Indeed, the United States (USA) or European Union (EU) pharmaceutical companies invested in 2016 approximately 18.3% and 14.4% of their own annual net turnover, respectively, in the research and development (R&D) phase of DDDP, with an increasing trend in the last years.
← all excerpts
Advanced Multi-Dimensional Cellular Models as Emerging Reality to Reproduce <i>In Vitro</i> the Human Body Complexity.
1
—
—